Crinetics climbs after reporting over $5 mln in Q4 net product revenue from recently launched drug

Crinetics Pharmaceuticals

05/01/2026 14:20

** Shares of Crinetics Pharmaceuticals CRNX.O up 19.8% at $56.01 premarket after reporting over $5 million in Q4 preliminary 2025 net product rev from recently launched Palsonify

** Palsonify approved in September 2025 for treating acromegaly, showing strong early sales and broad doctor adoption

** Company also reports positive Phase 2 study of atumelnant, an experimental oral drug aiming to treat rare hormone disorders by blocking a hormone receptor to balance hormone levels

** CEO Scott Struthers highlights broad prescriber base, favorable payer coverage, and over 200 enrollment forms in first three months post-approval

** CRNX stock up 0.39% this year after dropping 9% in 2025

 (Reporting by Tharuniyaa Lakshmi in Bengaluru)

 ((tharuniyaa@thomsonreuters.com))